Calaspargase-Pegol-Mknl Combined with BCL-2 and MCL-1 Inhibition for Acute Myeloid Leukemia
Dominique Bollino(West Virginia University), Ashkan Emadi(University of Maryland, Baltimore)
Cited by 1
Related Papers
Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy
|Leukemia & lymphoma/Leukemia and lymphoma|2013|56
Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia
|Cancer Chemotherapy and Pharmacology|2017|53
A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation
|Transplantation and Cellular Therapy|2019|43
Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management
|Journal of Oncology Pharmacy Practice|2019|42